senate Bill S2846

2009-2010 Legislative Session

Creates the lupus research enhancement program and the lupus research enhancement fund, and authorizes an appropriation

download bill text pdf

Sponsored By

Archive: Last Bill Status - In Committee


  • Introduced
  • In Committee
  • On Floor Calendar
    • Passed Senate
    • Passed Assembly
  • Delivered to Governor
  • Signed/Vetoed by Governor

do you support this bill?

Actions

view actions (3)
Assembly Actions - Lowercase
Senate Actions - UPPERCASE
Jan 06, 2010 referred to health
Mar 18, 2009 committee discharged and committed to health
Mar 04, 2009 referred to finance

S2846 - Bill Details

See Assembly Version of this Bill:
A8950
Current Committee:
Senate Health
Law Section:
Appropriations

S2846 - Bill Texts

view summary

view sponsor memo
BILL NUMBER: S2846

TITLE OF BILL :
An act to amend the public health law, in relation to creating the
lupus research enhancement program; to amend the state finance law, in
relation to creating the lupus research enhancement fund; and making
an appropriation therefor


PURPOSE OR GENERAL IDEA OF BILL :
To promote basic and clinical research programs designed to reduce or
prevent suffering from Lupus, by providing additional funding to state
academic medical institutions within the state currently conducting or
having an interest in conducting basic and clinical, social,
translational, technological, epidemiological, and behavioral research
on Lupus.

SUMMARY OF SPECIFIC PROVISIONS :
The Commissioner shall establish within the department a Lupus
research enhancement program through which the department shall make
grants to state academic medical institutions with the state currently
conducting or having an interest in conducting basic and clinical,
social, translational, technological epidemiological and behavioral
research on Lupus

The commissioner shall establish a multidisciplinary Lupus research
advisory council to monitor progress and make granting recommendations
to the department. The council shall be comprised of fifteen members
representing a broad range of expertise and experience. The council
shall be comprised as follows:

* at least three individuals with Lupus

* no more than two representatives from the department;

* at least five individuals from Lupus nonprofit health organizations;

* at least five-scientist s or clinicians with experience in Lupus and
who participates in various fields of scientific endeavor but not
limited to, the fields of biomedical research, social, translational,
behavioral and epidemiological research, and public health.

* the commissioner will choose from among the fifteen council members
one member to serve as chair.

An annual report shall be transmitted to the legislature on or before
December 31 as specified in the legislation.

The secretary of the Lupus research advisory council may accept
grants, services, and property from the federal government,
foundations, organizations, medical schools, and other entities that
may be available for the purpose of fulfilling the obligations of this
program.

The secretary of the research advisory council shall seek any federal
waiver or waivers that may be necessary to maximize funds from the
federal government.

JUSTIFICATION :
Lupus is a serious, complex, debilitating autoimmune disease that can
cause inflammation and tissue damage to virtually any organ system in
the body, including the skin, joints, other connective tissues, blood
and blood vessels, heart, lungs, kidney and brain.

The Lupus foundation of America, Inc. estimates that approximately 1.5
to 2 million American live with some form of lupus; Lupus affects
women nine times more often than men and 80 percent of newly diagnosed
cases of Lupus develop among women of childbearing age.

Lupus disproportionately affects women of color - it is two to three
times more common among African-Americans, Hispanics Asians and Native
Americans and is generally more prevalent in minority populations - a
health disparity that remains unexplained. According to the Center for
Disease Control and Prevention the rate of Lupus mortality has
increased since the 1970's and is higher among older African-American
women.

No new drugs have been approved by the U.S. Food and Drug
Administration specifically Lupus in nearly 40 years, and while
current treatments for the disease can be effective, they can lead to
damaging side effects. Despite the magnitude of Lupus and its impact
on individuals and families, health professional and public
understanding of Lupus remains low; only one of five Americans can
provide even basic information about Lupus, and awareness of lupus is
lowest among adults ages 18 to 34 - the age group most likely to
develop symptoms of Lupus.

PRIOR LEGISLATIVE HISTORY :
A.10511 of 2008

FISCAL IMPLICATIONS :
The sum of $250,000.00

EFFECTIVE DATE :
Immediately.
view full text
The Bill text is not available.

Comments

Open Legislation comments facilitate discussion of New York State legislation. All comments are subject to moderation. Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity or hate speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Comment moderation is generally performed Monday through Friday.

By contributing or voting you agree to the Terms of Participation and verify you are over 13.